Navigation Links
Kosan Receives Completed Special Protocol Assessment for TIME-1 Pivotal Phase 3 Trial of Tanespimycin in Multiple Myeloma
Date:9/6/2007

suming that the sponsor follows the protocol agreed-upon with the Agency, the sponsor has provided appropriate information to the Agency to support the protocol, the sponsor and the Agency agree to modify the protocol or a substantial scientific issue is identified after clinical testing has begun. In the absence of these developments, "completion of a SPA with FDA provides binding agreement relative to design and analysis of key Phase 3 trial(s) such that positive final results can lead to full NDA/ BLA approval." For more information about the Agency's Special Protocol Assessment process, see, http://www.fda.gov/cder/guidance/3764fnl.htm.

About Tanespimycin

Tanespimycin has been shown to induce apoptosis of drug-sensitive and drug-resistant multiple myeloma cell lines. Tanespimycin also inhibits expression of various cell surface cytokines, such as IGF-1R and IL-6R, that are involved in growth, survival and drug resistance of multiple myeloma cells. When used in combination with bortezomib, the destabilization of client proteins with tanespimycin while blocking their degradation with bortezomib promotes the accumulation of cytotoxic proteins, leading to cell death.

Kosan reported data from a Phase 1b trial of tanespimycin in combination with bortezomib at the 2007 annual meeting of the American Society for Clinical Oncology (ASCO) on 56 patients enrolled in 7 dose cohorts (100-340 mg/m2 of tanespimycin; 0.7-1.3 mg/m2 of bortezomib; tanespimycin administered via 1-hour infusion following the bortezomib dose 2 times per week every 2 weeks out of 3 weeks). Of these 56 patients, all had received multiple prior chemotherapy regimens (median of 4) and 67% had received bone marrow transplants.

In those patients who received tanespimycin across the range of doses tested and a dose of 1.0 or 1.3 mg/m2 of bortezomib, the overall response rate including complete, partial and mini
'/>"/>

SOURCE Kosan Biosciences Incorporated
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Kosan Presents Promising Phase 1 Data on Second-Generation Hsp90 Inhibitor, Alvespimycin, Showing Antitumor Activity in Refractory Breast and Ovarian Cancers at ASCO
2. Kosan Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Epothilone KOS-1584 at ASCO
3. Kosan Presents Data on Lead Hsp90 Inhibitor, Tanespimycin, Showing Promising Antitumor Activity in Multiple Myeloma at ASCO
4. Kosan Presents Preliminary Phase 2 Data Showing Antitumor Activity of Hsp90 Inhibitor Tanespimycin in Metastatic Melanoma at ASCO
5. Kosan Presents Preclinical Data on Nuclear Export Inhibitors, Novel Anticancer Agents, at AACR
6. Kosan Presents Preclinical Antitumor and Safety Data On Next-Generation Epothilone KOS-1803 at AACR
7. Kosan Presents Data on Cardiac Safety Profile of Hsp90 Inhibitor Tanespimycin (KOS-953) at AACR
8. Kosan Announces Data Presentations at Upcoming AACR Annual Meeting
9. Sirion Therapeutics Receives Orphan Drug Designation for Ophthalmic Drug to Treat Viral Eye Infection
10. Protalix BioTherapeutics, Inc. Receives Approval from the FDA to Initiate a Phase III Clinical Trial of prGCD
11. DUSA Pharmaceuticals Receives Orphan Drug Desi gnation for Levulan PDT to Treat Esophage al Dysplasia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/14/2009)... DENVER, Dec. 14 Corgenix Medical ... developer and marketer of diagnostic test kits, ... Massachusetts-based life sciences company, announced today a ... Galectin-3 diagnostic products in enzyme-linked immunosorbent assay ... BG Medicine is seeking regulatory clearance in ...
(Date:12/14/2009)... Sword Diagnostics, Inc. is pleased to ... has issued patent number 7,599,057 titled "Method ... Raman Scattering" to the company. The patent covers ... ,, "The issuance of this patent supports ... our continued development and commercialization," said Dave Dingott, ...
(Date:12/14/2009)... Southridge LLC ("Southridge"), an investment firm that provides ... announce that its affiliated fund has closed a private ... equity financing to Imaging Diagnostic Systems, Inc. (OTCBB: IMDS). ... growth of Imaging Diagnostic Systems, Southridge has paved a ... the field of early breast cancer detection," said Stephen ...
Breaking Medicine Technology:Corgenix and BG Medicine Announce Supply Agreement for BGM Galectin-3(TM) 2Southridge LLC Provides Funding Through Private Equity Agreement with Imaging Diagnostic Systems, Inc. 2Center on Media and Child Health Launches 26quot 3BAsk the Mediatrician 26quot 3B 48635 1Center on Media and Child Health Launches 26quot 3BAsk the Mediatrician 26quot 3B 48635 2Center on Media and Child Health Launches 26quot 3BAsk the Mediatrician 26quot 3B 48635 3Researchers identify 4 new targets for breast cancer 48632 1Researchers identify 4 new targets for breast cancer 48632 2Wii hab may enhance Parkinsons treatment 48629 1Wii hab may enhance Parkinsons treatment 48629 2
... 1 S*BIO Pte Ltd today announced the initiation of a ... inhibitor, in leading medical centers in Australia for patients with chronic ... The trial is designed to evaluate the safety and tolerability of ... to 50 patients. The Phase 1 part of the study ...
... Genaera Corporation (Nasdaq: GENR ) today announced ... (Study 102), the multiple ascending dose Phase 1b study ... diabetics. MSI-1436 is a novel therapeutic for the treatment ... and peripherally to regulate insulin and leptin pathways through ...
Other Medicine Technology:S*BIO Advances JAK2 Inhibitor SB1518 into Phase 1/2 Clinical Trial in Australia for the Treatment of Chronic Idiopathic Myelofibrosis 2S*BIO Advances JAK2 Inhibitor SB1518 into Phase 1/2 Clinical Trial in Australia for the Treatment of Chronic Idiopathic Myelofibrosis 3Genaera Begins Phase 1b Trial of Trodusquemine (MSI-1436) in Overweight and Obese Type 2 Diabetics 2Genaera Begins Phase 1b Trial of Trodusquemine (MSI-1436) in Overweight and Obese Type 2 Diabetics 3
(Date:12/15/2009)... Continues as Henry Ford Health System Joins the influx of ... , ... Hazlet, N.J. (PRWEB) December 15, ... talent acquisition solutions , announced today that Henry Ford ... to support its talent management needs. Henry Ford joins more ...
(Date:12/15/2009)... 15 "The entire San Diego Hospice and ... of Sol Price on December 14, 2009. Mr. Price ... loyalty and ethics in his business, community and personal ... who truly understood the responsibility of philanthropy and the ... will live on through his countless philanthropic efforts. We ...
(Date:12/14/2009)... -- In today,s academic medical centers, value analysis ... the University HealthSystem Consortium (UHC) has created a ... Cost Efficiencies in Health Care, to assist ... new materials, developed with the input of value ... guide to planning, implementing, and managing all phases ...
(Date:12/14/2009)... 14 Americold Realty Trust ("Americold") announced today ... S-11 with the U.S. Securities and Exchange Commission (the ... its common shares. The number of shares to be ... not yet been determined. The common shares to be ... by Americold. ,, The joint book-running managers of ...
(Date:12/14/2009)... -- United Dental Care (also known as Culver ... top-notch dental care in Southern California. We provide treatments ... braces (orthodontics) and periodontal treatments. Beverly Hills Dentist ... are staffed with experienced and trusted dentists who provide ... (Dr. E) is one of these trusted dentists. He ...
Breaking Medicine News(10 mins):Health News:iCIMS Emerges as Talent Management Solution of Choice for Henry Ford Health Systems 2Health News:iCIMS Emerges as Talent Management Solution of Choice for Henry Ford Health Systems 3Health News:iCIMS Emerges as Talent Management Solution of Choice for Henry Ford Health Systems 4Health News:San Diego Hospice and The Institute for Palliative Medicine on the Passing of Sol Price 2Health News:University HealthSystem Consortium Offers Value Analysis Professionals Insightful New Resources 2Health News:Americold Realty Trust Files Registration Statement for Proposed Initial Public Offering 2Health News:United Dental Care, Gentle Care, Trusted Dentists 2Health News:United Dental Care, Gentle Care, Trusted Dentists 3
... is to one day develop a therapy to help with ... Using genetically engineered cells and a virus as a delivery ... fiber in rat brains that controls movement. , This isn,t ... some neurons responsible for movement. But the new research showed ...
... a part , , MONDAY, April 6 (HealthDay News) -- Small children ... in other words, those who have more difficulty delaying gratification -- ... , The same seems true of young children who are ... whether these findings, from two studies published in the April issue ...
... (SEATTLE) The use of Avastin alone to treat ... it was safe and effective at delaying tumor progression, ... by a researcher at the Seattle Cancer Care Alliance., ... as alkylator-refractory anaplastic oligodendroglioma (AO), for which there is ...
... Education and Research InitiativesNEW YORK, April 6 ... leadership contributor with the National Thoroughbred Racing Association,s ... is to ensure the health and safety measures ... are addressed in a manner that will best ...
... finds , , MONDAY, April 6 (HealthDay News) -- The dangers ... researchers have now produced an overview of "light" smokers in ... smokers, which the U.S. Centers for Disease Control and ... country, is published in a series of studies and articles ...
... M. D. Anderson Cancer Center have discovered a gene that ... mutated in about half of all breast cancers. , The ... important in several other types of cancer, the team reports ... Causes for diminished PTEN protein levels in breast cancer absent ...
Other Medicine News:Health News:Team Regrows Neurons Controlling Movement in Rats 2Health News:Team Regrows Neurons Controlling Movement in Rats 3Health News:Kids Who Lack Self-Control May Be Prone to Weight Gain 2Health News:Kids Who Lack Self-Control May Be Prone to Weight Gain 3Health News:Avastin effective at delaying brain tumor progression in recurrent disease 2Health News:Pfizer Animal Health Becomes Leadership Contributor to the NTRA Safety and Integrity Alliance 2Health News:Pfizer Animal Health Becomes Leadership Contributor to the NTRA Safety and Integrity Alliance 3Health News:Researchers Profile the 'Light' Smoker 2Health News:Gene helps protect tumor suppressor in breast cancer 2
... can trust its capabilities will expand ... and glaucoma therapy in one system. ... the optimal system for photocoagulation, post-cataract ... The push of a button is ...
... YAG III is the new disruption ... in particular for applications in posterior ... the YAG laser is also used ... IOL polishing. It's another milestone in ...
... MEL 80 is a top quality Carl ... correction of vision defects even safer, more ... this ultramodern work platform are oriented towards ... the rapid recovery of vision. Key factors ...
An aid for advancing a pacemaker lead through the subcutaneous tissue of the chest wall to the pacemaker pocket....
Medicine Products: